QS-21
DRACPC ID DRACPC0100
Active Ingredients QS-21
Description A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant activity. When co-administered with vaccine peptides, QS21 may increase total antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses.
Synonyms NIAID VEU 016; Stimulon; QA 21V1; QS-21-Api
Type Biotech
Disease Melanoma, Genital herpes, HIV, Hepatitis (viral, B), Influenza
Classification
Immunoadjuvant
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence Not available
Sequence Length Not available
Modification Not available
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number DB05400
NCI Thesaurus Code C1478
UNII 61H83WZX3U GSRS
CAS 141256-04-4
Drug approval
Drug indication
Investigated for use/treatment in genital herpes, HIV infection, hepatitis (viral, B), influenza, malaria, melanoma, and viral infection.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00470574 | Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21 | Breast Cancer | Not Applicable | Treatment |
| NCT00036933 | Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21 | Prostate Cancer | Phase 1 | Treatment |
| NCT00004249 | Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy | Lung Cancer | Phase 2 | Treatment |
| NCT00004156 | Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21 | Breast Cancer | Phase 1 | Treatment |
| NCT05638698 | Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | Pancreas Cancer | Phase 2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
